Cargando…

Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ

Women with a diagnosis of ductal carcinoma in situ (DCIS) have a high risk of developing a second breast event (SBE). The immune system might play a role in trying to prevent a SBE. Patients diagnosed with DCIS were identified in the population-based cancer registry of Area Vasta Romagna from 1997 t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farolfi, Alberto, Petracci, Elisabetta, Serra, Luigi, Ravaioli, Alessandra, Bravaccini, Sara, Ravaioli, Sara, Tumedei, Maria Maddalena, Ulivi, Paola, Canale, Matteo, Puccetti, Maurizio, Falcini, Fabio, Folli, Secondo, Curcio, Annalisa, Rocca, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466557/ https://www.ncbi.nlm.nih.gov/pubmed/32974178 http://dx.doi.org/10.3389/fonc.2020.01486

Ejemplares similares

Easily detectable cytomorphological features to evaluate during ROSE for rapid lung cancer diagnosis: from cytology to histology
por: Ravaioli, Sara, et al.
Publicado: (2016)

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Bravaccini, Sara, et al.
Publicado: (2021)

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
por: Maltoni, Roberta, et al.
Publicado: (2020)

Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?
por: Bravaccini, Sara, et al.
Publicado: (2018)

New Biomarkers to Predict the Evolution of In Situ Breast Cancers
por: Bravaccini, S., et al.
Publicado: (2014)

Spotlight on PSMA as a new theranostic biomarker for bladder cancer
por: Tumedei, Maria Maddalena, et al.
Publicado: (2021)

Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold
por: Maltoni, Roberta, et al.
Publicado: (2020)

Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota
por: Pirini, Francesca, et al.
Publicado: (2023)

PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis
por: Bravaccini, Sara, et al.
Publicado: (2018)

Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?
por: Bronte, Giuseppe, et al.
Publicado: (2018)

The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial
por: Bravaccini, Sara, et al.
Publicado: (2020)

Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight
por: Cortesi, Michela, et al.
Publicado: (2021)

Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2017)

Androgen receptor in breast cancer: The “5W” questions
por: Ravaioli, Sara, et al.
Publicado: (2022)

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
por: Bronte, Giuseppe, et al.
Publicado: (2018)

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
por: Palleschi, Michela, et al.
Publicado: (2020)

Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer
por: Pietri, Elisabetta, et al.
Publicado: (2018)

Why the complications of COVID-19 patients differ in elderly and young cancer patients
por: Bravaccini, Sara, et al.
Publicado: (2022)

Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2019)

Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast
por: Jia, Huiqing, et al.
Publicado: (2022)

ACE2 and TMPRSS2 Potential Involvement in Genetic Susceptibility to SARS-COV-2 in Cancer Patients
por: Ravaioli, Sara, et al.
Publicado: (2020)

CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast
por: Rathore, Ankita Singh, et al.
Publicado: (2014)

What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Predictive Role of Telomerase Activity in the Clinical Outcome of Patients with Benign Lesions of the Uterine Cervix or CIN
por: Bravaccini, Sara, et al.
Publicado: (2012)

TMB in NSCLC: A Broken Dream?
por: Bravaccini, Sara, et al.
Publicado: (2021)

Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs)
por: Nguyen, Linh T., et al.
Publicado: (2010)

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
por: Poch, Michael, et al.
Publicado: (2018)

Expanding Roles of De Novo Lipogenesis in Breast Cancer
por: Simeone, Pasquale, et al.
Publicado: (2021)

Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?
por: Granato, Anna Maria, et al.
Publicado: (2004)

Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
por: Hall, MacLean, et al.
Publicado: (2016)

Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential
por: Jiménez-Reinoso, Anaïs, et al.
Publicado: (2021)

Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer
por: Fanale, Daniele, et al.
Publicado: (2022)

Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?
por: Maltoni, Roberta, et al.
Publicado: (2021)

Prognostic and predictive significance of tumor infiltrating lymphocytes for ductal carcinoma in situ
por: Xu, Fei-Fei, et al.
Publicado: (2021)

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
por: Canale, Matteo, et al.
Publicado: (2022)

Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma
por: Valentini, Davide, et al.
Publicado: (2018)

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
por: Kos, Zuzana, et al.
Publicado: (2020)

Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
por: Zhao, Yueshui, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_70jqo4gsq6l5m6akfsbe5ag26h